Compare Abbott Laboratories (ABT) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Toronto-Dominion Bank — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Toronto-Dominion Bank trades at $118.45 (market cap $200.57B). The key difference: Toronto-Dominion Bank is the larger of the two by market cap, and Toronto-Dominion Bank pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| ABT | TD | |
|---|---|---|
Market Cap | $166.94B | $200.57B |
Sector | Health | Financials |
52-Week High | $136.62 | $122.25 |
52-Week Low | $82.57 | $72.55 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TD stock trades at $121.43, up 1.79% today, with a bullish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. Analysts maintain a buy consensus with a $153 price target, and the company recently increased its dividend.
The outlook is positive given strong profitability, dividend growth, and analyst support, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers value with a P/E of 20.1 and robust ROE of 12.59%, though investors should monitor credit performance amid economic softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
